Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.92 - $2.11
Previous CloseN/A
Volume261.21K
Average Volume (3M)756.35K
Market Cap
$108.09M
Enterprise Value$108.93M
Total Cash (Recent Filing)$13.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.99
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding90,079,020
10 Day Avg. Volume497,900
30 Day Avg. Volume756,345
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-981.33
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$12.25Price Target Upside887.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical DataVidofludimus calcium has shown greater reductions in NfL levels in primary progressive MS patients compared to the only FDA-approved therapy, indicating potential as a major catalyst for shares.
Market OpportunityVidofludimus calcium could command share as an oral therapy in an MS market projected to surpass $45 billion.
Bears Say
Funding ConcernsInvestors need to see a CDP hazard ratio of less than 0.80 to have confidence in a viable path forward, particularly since the path is not yet funded.
Investment RisksRisks to an investment in Immunic are primarily clinical, regulatory, and commercial in nature, similar to other biotechnology companies.
---
Ownership Overview
9.12% Insiders
5.52% Mutual Funds
40.21% Other Institutional Investors
40.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.92 and its highest was $2.11 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $108.09M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Immunic’s earnings last quarter?
Currently, no data Available
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.24.
How many shares outstanding does Immunic have?
Immunic has 90,079,020 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
---
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (887.90% Upside)
$12.25 (887.90% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 118.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.25%
12-Months-Change
Fundamentals
Return on Equity
-216.24%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
---
IMUX Company Deck
---
IMUX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.Read More>---
IMUX Stock 12 Month Forecast
Average Price Target
$12.25
▲(887.90% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Cytokinetics
―
RedHill Biopharma
―
Viking Therapeutics
―
Best Analysts Covering IMUX
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
-1.26%
reiterated a buy rating 6 days ago
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -1.26% per trade.
---